Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. - Wikidata - awgldk - TriplyDB

Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors.

Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors.

http://www.wikidata.org/entity/Q37364079

about

Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients Oncolytic virus therapy: A new era of cancer treatment at dawn Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants Going viral: a review of replication-selective oncolytic adenoviruses Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data Activation of p53 by chemotherapeutic agents enhances reovirus oncolysis A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults AAV's anatomy: roadmap for optimizing vectors for translational success Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.Isolation of reovirus T3D mutants capable of infecting human tumor cells independent of junction adhesion molecule-A.Genetic and molecular alterations in pancreatic cancer: implications for personalized medicine.Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples Glycan engagement dictates hydrocephalus induction by serotype 1 reovirus.A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report New targeted therapies in pancreatic cancer.Molecular targeted approaches for treatment of pancreatic cancer.Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses The sweet spot: defining virus-sialic acid interactions.Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.Reovirus in cancer therapy: an evidence-based review Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy.Reovirus: a targeted therapeutic--progress and potential.Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells Enhanced cytotoxicity of reovirus and radiotherapy in melanoma cells is mediated through increased viral replication and mitochondrial apoptotic signalling.REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.Adenovirus as a new agent for multiple myeloma therapies: Opportunities and restrictions.Progress of oncolytic viruses in sarcomas.Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer.Current status of gene therapy for breast cancer: progress and challenges.The oncolytic virus, pelareorep, as a novel anticancer agent: a review.Toll like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal cancer African Swine Fever Virus NP868R Capping Enzyme Promotes Reovirus Rescue during Reverse Genetics by Promoting Reovirus Protein Expression, Virion Assembly, and RNA Incorporation into Infectious Virions.Oncolytic virotherapy for multiple myeloma: past, present, and future.

P2860

Q24617027-50F2D0E1-6B6D-4BE0-8992-43800747AFC7 Q26739714-82D16BB0-F3E6-46D6-9109-D70534AA2B4E Q26739777-604EFC13-938E-40D0-B217-DDCA110D96BA Q26750568-452AF99F-1881-4C99-B819-465F9717C4E3 Q26752807-1CB7B4B5-9EDC-4189-92CF-4E00C3C7DA33 Q26775033-14BB34F7-DE1B-407C-A816-B42A088E33CF Q26797520-E1A0900B-D8D7-4BD4-8258-E667877CD9B2 Q26801501-D7EE1A15-FED2-4963-A317-A62B628A8BBD Q28485141-E1A16496-0135-492C-9AC4-8060FA023DAC Q33418048-3074AF2F-F7F0-4E0B-95A5-64E8C2CDE390 Q33586985-DB96BB75-A176-4AF6-A9F6-E672A22D898E Q33659389-A949207B-3E11-4534-8A0E-8B7DE9598399 Q34393001-AC1B24CC-CC8C-4E73-A2AC-BF6EC1529BA5 Q34460916-7DDAABFB-2830-46AA-B38B-820851B63A41 Q34657038-7B1E9B27-8C09-4650-B7D0-7251A2FF36C3 Q34763999-0B7AC4DE-89A5-485B-8AB8-69F1D66DCECE Q35172332-1883579D-0D88-4CFE-8AA9-34E2578EAD82 Q35224368-E0833BBD-F17A-4C45-BD87-7DC57B68404A Q35651453-616D6ECB-C55E-4EFA-A31F-9C33234B30B5 Q36174910-1A1503AB-2545-41B4-83A2-D09E27EACA4E Q36298608-952B5C0F-9666-420A-A98F-E40B47C665B4 Q36582819-42030CFB-C932-4798-A4F7-90875A6375DB Q36685206-9E7C35F3-5F43-419E-8544-7B3BD8ACE1C6 Q36766032-74A0D2B1-F3C0-4A3D-9C17-BCF88DC81F7C Q36766052-464BDFF3-0319-4DF6-A44B-E3FEE386E9C4 Q37031909-9DB37433-6DF9-452C-93E9-FEC4BEC2112C Q37347236-ECA99AA4-8DBB-45BC-8399-3F29D84EE6C9 Q37360585-9B4235FB-1E01-439D-80E9-91FE9C10973C Q37360608-710FB730-1F28-4A52-9494-5F46A77B2273 Q37477574-999F6E4D-B76F-42B9-A1F9-6A3B77BE9875 Q37565521-8F4D8077-4BC0-40E6-88F1-DD42FB297EFA Q37602536-9B634C58-DDBC-4F22-8524-CA16E02BE8EF Q37977063-F03AB4CB-EE8B-4A1A-96C0-DF096B0142A9 Q37982449-046C75EC-1FBD-4D35-AE85-F71C99DD4CAD Q38058884-4F3020A0-059D-4DC9-AC29-BC8A25D2E92A Q38270806-098154FF-44EA-4626-9D74-7631519F328B Q38360781-697C7E2F-7EF4-4143-AAEE-7495EBBF3E95 Q38706944-43D4D6FA-C571-44B1-B364-F7CE74E8376A Q38712130-DB652016-2302-46F9-BEC5-C893CA1A82D0 Q38803056-6A26E5F7-0417-4AF3-B773-4B9A26F23DD9

P2860

Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors.

http://www.wikidata.org/entity/Q37364079

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Intravenous administration of ...... ts with advanced solid tumors.

@en

Intravenous administration of ...... ts with advanced solid tumors.

@nl

type

label

Intravenous administration of ...... ts with advanced solid tumors.

@en

Intravenous administration of ...... ts with advanced solid tumors.

@nl

prefLabel

Intravenous administration of ...... ts with advanced solid tumors.

@en

Intravenous administration of ...... ts with advanced solid tumors.

@nl

P1433

Q37364079-86EED2E5-B353-4EB7-B494-5FA8932D4B74

P1476

Q37364079-4BFFE4E2-7945-4408-9871-46CDE52A6D2B

P2093

Q37364079-07EDCD07-C383-4DB2-BEBB-2BD742915835

Q37364079-166D11BC-48C8-4866-A275-60D2902AB3A2

Q37364079-217E9442-2026-4841-A32C-1E13EFC2CB88

Q37364079-2B06132E-62EF-4C52-B692-F7448A3ECA5C

Q37364079-2EA327B5-4B84-4138-8EAA-7583EECC7E14

Q37364079-8CF352BC-F5D8-47A6-A816-2BF37D57E9A2

Q37364079-926C67D0-F23D-4F59-A7EF-36784E7E9F06

Q37364079-947ADEC7-7268-4DC3-8CBA-7E8CA30E8CE9

Q37364079-A501F528-6DBC-4539-958C-570085821E1B

Q37364079-B652A083-0E38-46BD-B224-2A0607C052AA

P2860

Q37364079-07775BB8-956B-4DA4-912B-81F2EE4F537D

Q37364079-0C25ECBB-D038-45F4-803B-043867B2BE44

Q37364079-16262016-5AE8-4061-851E-A252B53E7974

Q37364079-18F1F0D9-998E-4101-8AFF-EE59EFD135FD

Q37364079-1E47DADC-6B2D-4BE5-ABA0-622A04EFA3F6

Q37364079-1ECA8D2D-07B4-48B7-9BF7-464419B5DB83

Q37364079-42409821-71B0-4FA0-AC1D-74576C1B27AB

Q37364079-468A8C75-81C0-4572-9FD4-5C8D85ADAD94

Q37364079-4970DADF-D28E-471B-B873-F0CBCD5140B1

Q37364079-4996B396-E166-4031-83F8-9FF04AE11F31

P2888

Q37364079-0F144A77-84DF-47DB-9B51-3172657D496A

P304

Q37364079-8EA2E8DE-1BCE-4F0E-99E3-8D66821503B5

P31

Q37364079-E53B1CB8-47CC-4359-9510-DE21BFA4B460

P356

Q37364079-70DD4545-8103-4013-892A-B2F65DE519D7

P433

Q37364079-7007A2D5-F244-41CB-B0BC-361CCA4794B0

P478

Q37364079-CCEAB351-FFEA-405D-B695-537436F84CD9

P577

Q37364079-2DD11837-D790-47B9-9D4C-C8FFFA28DE8E

P698

Q37364079-2015529E-8114-46ED-97D0-F4721FFCBE5F

P921

Q37364079-90665F80-ED66-4945-B4B0-66A42177ED78

P932

Q37364079-F3FE4F72-7461-4048-9C04-951DA2F2B01D

P356

S10637-009-9279-8

P1433

Investigational New Drugs

P1476

Intravenous administration of ...... ts with advanced solid tumors.

@en

P2093

Benny Wong

http://www.w3.org/2001/XMLSchema#string

George M Gill

http://www.w3.org/2001/XMLSchema#string

Imran Chaudhary

http://www.w3.org/2001/XMLSchema#string

John M Mariadason

http://www.w3.org/2001/XMLSchema#string

Karl Mettinger

http://www.w3.org/2001/XMLSchema#string

Kavita K Desai

http://www.w3.org/2001/XMLSchema#string

Mark Einstein

http://www.w3.org/2001/XMLSchema#string

Matthew Coffey

http://www.w3.org/2001/XMLSchema#string

Mohammad H Ghalib

http://www.w3.org/2001/XMLSchema#string

Radharani Gollamudi

http://www.w3.org/2001/XMLSchema#string

P2860

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

ras oncogenes in human cancer: a review

Viruses in the treatment of cancer.

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.

Reovirus therapy of tumors with activated Ras pathway.

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.

Sensitive sequencing method for KRAS mutation detection by Pyrosequencing.

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress.

Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection

P2888

s10637-009-9279-8

P304

641-649

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-009-9279-8

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19572105

http://www.w3.org/2001/XMLSchema#string

P921

P932

3851036

http://www.w3.org/2001/XMLSchema#string